Periodontal Attachment LossNCT03756493
Added Benefit of L-PRF to Autogenous Bone Graft in the Treatment of Mandibular Degree II Furcation Defects
A study testing Periodontal Surgery with OFD+ABG+L-PRF, Periodontal Surgery with OFD+ABG and Periodontal Surgery OFD in people with Periodontal Attachment Loss and Periodontal Bone Loss, run by G. d'Annunzio University at 1 site in Italy.
Trial summary
Different therapeutic approaches have been proposed for the treatment of furcation defects and the regeneration of periodontium within the furcation area is considered one of the most challenging aspect of surgical periodontal therapy. Read more about this study
- Who is it for?
- Ages 18 to 70 yearsHealthy volunteers can take part
- Conditions the study is for
- Periodontal Attachment Loss, Periodontal Bone Loss
- What is being tested?
- Periodontal Surgery with OFD+ABG+L-PRF, Periodontal Surgery with OFD+ABG and Periodontal Surgery OFD
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 54 participants
- Where
- 1 siteItaly
- Study dates
- 5 Dec 2018to 4 May 2020
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 70 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- a Full-Mouth Plaque Score (FMPS) and a Full-Mouth Bleeding Score (FMBS) < 20% at the time of surgery;
- to have at least 20 teeth;
- at least 1 mandibular molar with buccal or lingual degree II furcation defects, with no mobility and with horizontal CAL (HCAL) > 3 mm and vertical probing depth in the central-vestibular or central-lingual site >= 5 mm after non surgical treatment.
Who cannot join
- systemic diseases;
- medications affecting periodontal status during the previous 6 months;
- pregnant or lactating;
- smokers;
- periodontal therapy in the 2 previous years;
- periapical endodontic lesions;
- dental mobility.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: The Added Benefit of L-PRF to Autogenous Bone Graft in the Treatment of Degree II Furcation Involvements in Mandibular Molars
Different therapeutic approaches have been proposed for the treatment of furcation defects and the regeneration of periodontium within the furcation area is considered one of the most challenging aspect of surgical periodontal therapy.
Periodontal regeneration is a highly predictable therapeutic option for the treatment of different furcation defects, particularly class II furcation involvements in the lower molars.
Read more
In particular, the application of a combined therapeutic approach (i.e., barrier, bone re-placement graft with or without biological agents) seems to offer better results as compared with monotherapeutic treatments.
Several studies have demonstrated that platelet concentrates, such as platelet-rich plasma (PRP), platelet-derived growth factor (PDGF) and, more recently, leukocyte and platelet-rich fibrin (L-PRF) can represent new therapeutic options for bone regeneration procedures by increasing the healing potential of natural blood clot in the surgical site.
Leukocyte and Platelet-rich fibrin (L-PRF) is a second-generation platelet concentrate, developed by Choukroun et al. It is prepared without the addition of any anticoagulants and consists of a slowly polymerized complex fibrin network which incorporates leukocytes, glycan chains, structural glycoproteins and an high concentration of growth factors such as transforming growth factor β (TGF-B), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF). The three-dimensional architecture and the specific biochemical properties, which facilitate the wound healing processes, have led to a widespread use of this biomaterial in plastic surgery, maxillofacial surgery, oral and periodontal surgery.
A large clinical and histological evidence supports the concept that autogenous bone grafts (ABG) are highly effective regenerative materials in the treatment of intrabony defects. Moreover, with respect to the treatment of furcation defects, outcome data from a number of studies generally indicate positive clinical benefits with the use of bone grafts in the treatment of Class II furcations.
Therefore, on the basis of such considerations, the aim of this study was to evaluate the effectiveness of a combined regenerative treatment by L- PRF and ABG in the treatment of mandibular molars degree II furcation defects and to compare the outcomes of such a treatment with those from (OFD)+ABG and OFD alone treatments.
Read the detailed description
Experimental Design. This randomized, comparative and clinical trial will be designed to evaluate the clinical and radiographic outcomes 6 months after three treatment modalities of mandibular degree II furcation defects.
The patients study will exhibit buccal or lingual mandibular degree II furcation defects; all experimental sites will be accessed with a SPPF procedure. L- PRF and autogenous bone graft (ABG) will be applied to the debrided defects in the OFD+ABG+L-PRF group; the OFD+ABG group will receive only ABG and the OFD group will be treated with Open Flap Debridement (OFD) alone.
Study Population. At least fifty-four patients, aged 18 to 70 years old, affected by moderate-to-severe chronic periodontitis, will be selected for this study and treated at the Operating Unit of Periodontology and Oral Hygiene of the Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" Chieti-Pescara University, Italy. Each patient will participate in the study with a single experimental site.
The participants will receive verbal and written information and will sign a consent form approved by the Ethical Committee of the G. D'Annunzio University of Chieti medical faculty. The study protocol is in accordance with the Declaration of Helsinki of 1975, as revised in 2013.
Each defect will be assigned a defect number and will be randomly allocated to one of the three treatment regimens. Assignment will be performed by a custom made computer-generated table. To conceal allocation, opaque envelops will be assigned to the specific experimental site and will be opened during surgery.
Four months before the surgical treatment, all 54 patients will undergo non-surgical periodontal treatment consisting of supragingival and subgingival scaling and root planing (SRP) by ultrasonic instruments and hand curets and motivational instructions on oral home care.
Complete oral and periodontal examinations will be performed for each patient before and 4 months after the non-surgical treatment. These will include full mouth plaque score (FMPS), full mouth bleeding score (FMBS), probing depth (PD), vertical clinical attachment level (VCAL), horizontal clinical attachment level (HCAL), and gingival recession (GR) for six sites per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual/ palatal, mid-lingual/palatal, and disto-lingual/palatal sites). The measurements will be recorded using a University of North Carolina (UNC-15, HuFriedy, Chicago, Illinois, USA) periodontal probe.
Clinical measurements at mid-buccal or mid-lingual experimental sites will be taken immediately before surgical treatment (baseline) and 6 months after treatment, by the same experienced examiner (MP), who will be masked to the treatment. The primary outcome of the study will be HCAL gain at 6 months.
Radiographic Measurements. Preoperative and 6 months postoperative standardized radiographs will be taken by the paralleling technique using an individual film-holder device consisting of a bite block rigidly connected to an acrylic dental splint to achieve identical film placement at each evaluation.
The radiographs will be digitized using an image processing device, after choosing the standard scan settings (600 dots per inch and 256 levels of gray).
Measurements related to vertical bone level (VBL) will be performed using a dedicated software and calculating the distance between the furcation fornix and the bottom of the defect.
Before surgery, from each patient of all groups, to avoid unblinding, 30 ml of blood was collected in three 10-ml sterile tubes without anticoagulant, and it was quickly centrifuged‖‖ at 3,000 revolutions/minute for 10 minutes.The fibrin clot (L-PRF) was collected and squeezed in the L-PRF Box to form three membranes.
Surgical Technique. All the surgeries will be performed by the same experienced clinician. In all groups, after local anaesthesia, mucoperiosteal SPPFs will be raised. Mesial and distal vertical releasing incisions will be performed to allow more visibility and defects accessibility. After flap elevation, flap mobility will be tested to ensure that primary closure of the wound could be achieved through tension-free suturing. The granulation tissue adherent to the alveolar bone will be removed to provide full access and visibility to the root and bone surfaces. SRP will be performed. ABG material will be collected using bone scrapers in OFD+ABG+L-PRF group and OFD+ABG group.
In the OFD+ABG+L-PRF group , one L-PRF membrane cutted into small pieces and mixed with ABG will be placed in the furcation defect. The other PRF membranes in each patient will be placed over the grafted defect and will be sutured with an absorbable suture. The OFD+ABG group defects will be grafted only with ABG and will be not covered by a L-PRF membrane. The OFD group defect will be treated only with open flap debridement. Finally the flap will be repositioned and horizontal mattress and interrupted sutures will be carried out.
- Conditions
- Periodontal Attachment Loss, Periodontal Bone Loss
- Being tested
- Periodontal Surgery with OFD+ABG+L-PRF, Periodontal Surgery with OFD+ABG, Periodontal Surgery OFD
- Keywords
- Platlet rich fibrin, Bone graft, Furcation defects
- Medical subject headings
- Periodontal Attachment Loss, Alveolar Bone Loss, Furcation Defects
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Periodontal Surgery with OFD+ABG+L-PRFProcedure or surgery
Patients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material.
Periodontal Surgery with OFD+ABGProcedure or surgery
Patients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material.
Periodontal Surgery OFDProcedure or surgery
Patients will be treated by Open Flap Debridement without use of filling material.
| Study group | Role | What they receive |
|---|---|---|
| OFD+ABG+L-PRF treated patients | Experimental | Periodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures. Receives: Procedure: Periodontal Surgery with OFD+ABG+L-PRF |
| OFD+ABG treated patients | Active comparator | Periodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures. Receives: Procedure: Periodontal Surgery with OFD+ABG |
| OFD treated patients | Active comparator | Periodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures. Receives: Procedure: Periodontal Surgery OFD |
What is being measured
The primary outcome is the main question the study is designed to answer.
Horizontal Clinical Attachment Gain
The periodontal probe was inserted into the furcation area, perpendicular to a horizontal one which was placed on the buccal or lingual aspect of the involved tooth.
Measured: 6 months
Secondary outcomes (4)
Vertical Bone Level
Radiographic distance between the fornix of furcation and the bottom of the defect.
Measured: 6 months
Vertical Clinical Attachment Gain
Change of the distance between the cementum-enamel junction and the depth of the probable site.
Measured: 6 months
Pocket Probing Depth
Change of the distance between the gingival margin and the depth of the probable site.
Measured: 6 months
Gingival recession
Change of the distance between the cementum-enamel junction and the gingival margin of the probable site.
Measured: 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Nov 2018
- Study start5 Dec 2018
- Primary completion4 May 2020
- Study completion4 May 2020
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Periodontal Attachment LossStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind
- Who is masked
- Participant, Care provider, Investigator
- Enrolment
- 54 participants (actual)
Sponsor and investigators
- Lead sponsor
- G. d'Annunzio University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Michele Paolantonio, G. d'Annunzio University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03756493
- Sponsor's protocol ID
- 11042017
- Status last verified
- Sep 2021
- First submitted
- 26 Nov 2018
- Last updated
- 14 Sep 2021
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 14 Sep 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Added Benefit of L-PRF to Autogenous Bone Graft in the Treatment of Degree II Furcation Involvements in Mandibular Molars
- ClinicalTrials.gov ID
- NCT03756493
- Acronym / sponsor ID
- 11042017
- Conditions
- Periodontal Attachment Loss, Periodontal Bone Loss
- Keywords
- Platlet rich fibrin, Bone graft, Furcation defects
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 54 participants (actual)
- Lead sponsor
- G. d'Annunzio UniversityUniversity, hospital or other
- Study start
- 5 Dec 2018 (actual)
- Primary completion
- 4 May 2020 (actual)
- Study completion
- 4 May 2020 (actual)
- First posted
- 28 Nov 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Different therapeutic approaches have been proposed for the treatment of furcation defects and the regeneration of periodontium within the furcation area is considered one of the most challenging aspect of surgical periodontal therapy.
Periodontal regeneration is a highly predictable therapeutic option for the treatment of different furcation defects, particularly class II furcation involvements in the lower molars.
In particular, the application of a combined therapeutic approach (i.e., barrier, bone re-placement graft with or without biological agents) seems to offer better results as compared with monotherapeutic treatments.
Several studies have demonstrated that platelet concentrates, such as platelet-rich plasma (PRP), platelet-derived growth factor (PDGF) and, more recently, leukocyte and platelet-rich fibrin (L-PRF) can represent new therapeutic options for bone regeneration procedures by increasing the healing potential of natural blood clot in the surgical site.
Leukocyte and Platelet-rich fibrin (L-PRF) is a second-generation platelet concentrate, developed by Choukroun et al. It is prepared without the addition of any anticoagulants and consists of a slowly polymerized complex fibrin network which incorporates leukocytes, glycan chains, structural glycoproteins and an high concentration of growth factors such as transforming growth factor β (TGF-B), platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF). The three-dimensional architecture and the specific biochemical properties, which facilitate the wound healing processes, have led to a widespread use of this biomaterial in plastic surgery, maxillofacial surgery, oral and periodontal surgery.
A large clinical and histological evidence supports the concept that autogenous bone grafts (ABG) are highly effective regenerative materials in the treatment of intrabony defects. Moreover, with respect to the treatment of furcation defects, outcome data from a number of studies generally indicate positive clinical benefits with the use of bone grafts in the treatment of Class II furcations.
Therefore, on the basis of such considerations, the aim of this study was to evaluate the effectiveness of a combined regenerative treatment by L- PRF and ABG in the treatment of mandibular molars degree II furcation defects and to compare the outcomes of such a treatment with those from (OFD)+ABG and OFD alone treatments.
Detailed description
Experimental Design. This randomized, comparative and clinical trial will be designed to evaluate the clinical and radiographic outcomes 6 months after three treatment modalities of mandibular degree II furcation defects.
The patients study will exhibit buccal or lingual mandibular degree II furcation defects; all experimental sites will be accessed with a SPPF procedure. L- PRF and autogenous bone graft (ABG) will be applied to the debrided defects in the OFD+ABG+L-PRF group; the OFD+ABG group will receive only ABG and the OFD group will be treated with Open Flap Debridement (OFD) alone.
Study Population. At least fifty-four patients, aged 18 to 70 years old, affected by moderate-to-severe chronic periodontitis, will be selected for this study and treated at the Operating Unit of Periodontology and Oral Hygiene of the Department of Medical, Oral and Biotechnological Sciences, "G. D'Annunzio" Chieti-Pescara University, Italy. Each patient will participate in the study with a single experimental site.
The participants will receive verbal and written information and will sign a consent form approved by the Ethical Committee of the G. D'Annunzio University of Chieti medical faculty. The study protocol is in accordance with the Declaration of Helsinki of 1975, as revised in 2013.
Each defect will be assigned a defect number and will be randomly allocated to one of the three treatment regimens. Assignment will be performed by a custom made computer-generated table. To conceal allocation, opaque envelops will be assigned to the specific experimental site and will be opened during surgery.
Four months before the surgical treatment, all 54 patients will undergo non-surgical periodontal treatment consisting of supragingival and subgingival scaling and root planing (SRP) by ultrasonic instruments and hand curets and motivational instructions on oral home care.
Complete oral and periodontal examinations will be performed for each patient before and 4 months after the non-surgical treatment. These will include full mouth plaque score (FMPS), full mouth bleeding score (FMBS), probing depth (PD), vertical clinical attachment level (VCAL), horizontal clinical attachment level (HCAL), and gingival recession (GR) for six sites per tooth (mesio-buccal, mid-buccal, disto-buccal, mesio-lingual/ palatal, mid-lingual/palatal, and disto-lingual/palatal sites). The measurements will be recorded using a University of North Carolina (UNC-15, HuFriedy, Chicago, Illinois, USA) periodontal probe.
Clinical measurements at mid-buccal or mid-lingual experimental sites will be taken immediately before surgical treatment (baseline) and 6 months after treatment, by the same experienced examiner (MP), who will be masked to the treatment. The primary outcome of the study will be HCAL gain at 6 months.
Radiographic Measurements. Preoperative and 6 months postoperative standardized radiographs will be taken by the paralleling technique using an individual film-holder device consisting of a bite block rigidly connected to an acrylic dental splint to achieve identical film placement at each evaluation.
The radiographs will be digitized using an image processing device, after choosing the standard scan settings (600 dots per inch and 256 levels of gray).
Measurements related to vertical bone level (VBL) will be performed using a dedicated software and calculating the distance between the furcation fornix and the bottom of the defect.
Before surgery, from each patient of all groups, to avoid unblinding, 30 ml of blood was collected in three 10-ml sterile tubes without anticoagulant, and it was quickly centrifuged‖‖ at 3,000 revolutions/minute for 10 minutes.The fibrin clot (L-PRF) was collected and squeezed in the L-PRF Box to form three membranes.
Surgical Technique. All the surgeries will be performed by the same experienced clinician. In all groups, after local anaesthesia, mucoperiosteal SPPFs will be raised. Mesial and distal vertical releasing incisions will be performed to allow more visibility and defects accessibility. After flap elevation, flap mobility will be tested to ensure that primary closure of the wound could be achieved through tension-free suturing. The granulation tissue adherent to the alveolar bone will be removed to provide full access and visibility to the root and bone surfaces. SRP will be performed. ABG material will be collected using bone scrapers in OFD+ABG+L-PRF group and OFD+ABG group.
In the OFD+ABG+L-PRF group , one L-PRF membrane cutted into small pieces and mixed with ABG will be placed in the furcation defect. The other PRF membranes in each patient will be placed over the grafted defect and will be sutured with an absorbable suture. The OFD+ABG group defects will be grafted only with ABG and will be not covered by a L-PRF membrane. The OFD group defect will be treated only with open flap debridement. Finally the flap will be repositioned and horizontal mattress and interrupted sutures will be carried out.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, care provider, investigator)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| OFD+ABG+L-PRF treated patients | Experimental | Procedure: Periodontal Surgery with OFD+ABG+L-PRFPeriodontal surgery with Leukocyte and Platelet Rich Fibrin (L-PRF) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. Autogenous bone graft mixed with cutted L-PRF will be applied to the furcation defects; then, a L-PRF membrane is positioned above the filling material. Finally the flap will be coronally positionated and sutured by interrupted sutures. |
| OFD+ABG treated patients | Active comparator | Procedure: Periodontal Surgery with OFD+ABGPeriodontal surgery with Autogenous Bone Graft (ABG) is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. ABG will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures. |
| OFD treated patients | Active comparator | Procedure: Periodontal Surgery OFDPeriodontal surgery with Open Flap Debridement is performed, after local anaesthesia, mucoperiosteal SPPFs will be raised. No grafts will be applied to the furcation defects. Finally the flap will be coronally positioned and sutured by interrupted sutures. |
Who may qualify
- Ages
- 18 to 70 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- a Full-Mouth Plaque Score (FMPS) and a Full-Mouth Bleeding Score (FMBS) < 20% at the time of surgery;
- to have at least 20 teeth;
- at least 1 mandibular molar with buccal or lingual degree II furcation defects, with no mobility and with horizontal CAL (HCAL) > 3 mm and vertical probing depth in the central-vestibular or central-lingual site >= 5 mm after non surgical treatment.
Key exclusion criteria (7 listed)
- systemic diseases;
- medications affecting periodontal status during the previous 6 months;
- pregnant or lactating;
- smokers;
- periodontal therapy in the 2 previous years;
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Periodontal Surgery with OFD+ABG+L-PRFPatients will be treated by periodontal surgical flaps with the addition of L-PRF+ Autogenous Bone Graft filling material. | Procedure or surgery | OFD+ABG+L-PRF treated patients |
| Periodontal Surgery with OFD+ABGPatients will be treated by periodontal surgical flaps with the addition of Autogenous Bone Graft filling material. | Procedure or surgery | OFD+ABG treated patients |
| Periodontal Surgery OFDPatients will be treated by Open Flap Debridement without use of filling material. | Procedure or surgery | OFD treated patients |
Primary outcome
Horizontal Clinical Attachment Gain
Time frame: 6 months
The periodontal probe was inserted into the furcation area, perpendicular to a horizontal one which was placed on the buccal or lingual aspect of the involved tooth.
4 secondary outcomes
Vertical Bone Level
Time frame: 6 months
Vertical Clinical Attachment Gain
Time frame: 6 months
Pocket Probing Depth
Time frame: 6 months
Gingival recession
Time frame: 6 months
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Sep 2021.
- Individual participant dataSharing planned: Undecided
Related trials for Periodontal Attachment Loss
Recruiting
Regenerative Gel (Emdogain®) for Healing After Wisdom Tooth Extraction
Alveolar Bone Loss, Periodontal Pocket
Recruiting
PRF as Adjunct to Subgingival Instrumentation in Step 2 Periodontal Therapy
Periodontitis, Periodontal Inflammation
Recruiting
Hyaluronic Acid and Polynucleotides for Supra-bony Defects
Periodontal Diseases, Wound Heal
Recruiting
Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects
Periodontal Diseases, Periodontal Attachment Loss
Active, not recruitingObservational study
Evaluation of OHIP-14 and OSHIP-14 in Patients With Varying Periodontal Disease
Periodontal Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Periodontal Surgery with OFD+ABG+L-PRF, Periodontal Surgery with OFD+ABG and Periodontal Surgery OFD in people with Periodontal Attachment Loss and Periodontal Bone Loss, run by G. d'Annunzio University at 1 site in Italy.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 14 Sep 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Horizontal Clinical Attachment Gain (time frame: 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Sep 2021.